Scholar Rock Holding Corporation (SRRK) News
Filter SRRK News Items
SRRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRRK News Highlights
- For SRRK, its 30 day story count is now at 3.
- Over the past 9 days, the trend for SRRK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ROCK are the most mentioned tickers in articles about SRRK.
Latest SRRK News From Around the Web
Below are the latest news stories about SCHOLAR ROCK HOLDING CORP that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., December 19, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET). |
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., December 15, 2023--Scholar Rock (NASDAQ: SRRK; "The Company"), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of 44,900 shares of common stock and inducement |
Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK)Edward Myles, the Chief Operating Officer and Chief Financial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), has recently sold 24,914 shares of the company's stock. |
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call TranscriptScholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript November 7, 2023 Rushmie Nofsinger: Good morning. I’m Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our Q3 2023 Business Update Call. This call is audio-only. You can access the slides […] |
Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial ResultsCompany Completes $98 Million Public Offering, Extends Cash Runway into H2 2025 |
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business ProgressCAMBRIDGE, Mass., November 07, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2023. |
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Insider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK)On November 2, 2023, Edward Myles, the COO & CFO of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 35,007 shares of the company. |
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued TolerabilityCAMBRIDGE, Mass., November 03, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint inhibitor therapy in patients with advanced cancer. These data will be presente |
Scholar Rock to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., November 02, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: |